celares GmbH, established 2003, is a Contract Development and Manufacturing Organization (CDMO) providing customized services as well as innovative solutions for antibody-drug conjugates or ADCs.
The company uniquely combines expertise in both synthetic and protein chemistry and has experiences in handling toxins, synthesis of activated linkers, toxin-linker-precursors, and ADCs.? celares also offers its proprietary PaSmax? linker technology for next generation ADCs. PaSmax? linkers are made from non-dispersed PEGs and are capable of:
- Increasing DAR without the need for additional attachment sites;
- Modulating solubility of the toxin;
- Reducing risk of aggregation, and
- Simplifying analytics. In particular, antibody fragments, site-specifically modified antibodies, or scaffold proteins benefit from this technology.
celares offers services ranging from early feasibility studies to a complete development of the manufacturing process and analytical methods. Several of celares? developments and optimized processes have been established in a GMP environment for the manufacturing of drug product for clinical trials and market supply over the last years. celares has clients from pharma and biotech all over the world.
celares operates on a modular business model. Feasibility studies, also including PaSmax? conjugates, as well as customized developments and manufacturing are offered on a fee-for-service basis. Development of ADC candidates employing celares? proprietary technologies requires milestones and royalty bearing license agreements.
Otto Warburg Building D80